CeraPedics, Inc. Appoints Glen A. Kashuba as Chief Executive Officer and Jeffrey G. Marx, Ph.D., as President and Chief Operating Officer
5/16/2013 11:07:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Cerapedics, Inc. announced today that its Board of Directors has appointed Glen A. Kashuba as the company’s new chief executive officer, effective June 1, 2013.
Kashuba formerly served as worldwide president of Spine & Bone Healing Technologies, Inc., a Biomet company, while concurrently serving as senior vice president on Biomet’s worldwide operating board, encompassing Biomet’s orthopedics, spine, trauma, biologics and sports medicine businesses.
“Glen is a well-known and respected leader in the spine and orthopedics industries. He had many opportunities available to him and we are delighted that he has chosen to join Cerapedics to lead the company through several upcoming major value inflection points,” said Jonathan Silverstein, chairman of Cerapedics and general partner at OrbiMed.
“I am honored to join Cerapedics as CEO and work with the talented group of individuals who have built this company and brought its unique products to market,” Kashuba said. “Our goal is for Cerapedics to be a leader in the global bone biologics market by providing a powerful and safe orthobiologics solution to the clinicians and patients we serve. I look forward to leading the Cerapedics team to that goal.”
Kashuba’s tenure at Biomet also included the role of worldwide president for Biomet Spine and Trauma, where he had profit and loss responsibility for all functional areas, including sales force management and supply chain optimization. Kashuba’s commercial responsibilities included managing sales of greater than $400 million, driven by more than 500 direct and independent sales representatives. Kashuba was also responsible for launching more than 25 new products into the market during his tenure at Biomet.
Prior to his leadership roles at Biomet, Kashuba held a number of division president roles at Johnson & Johnson where he served as worldwide president for Cordis Endovascular and Neurovascular and as worldwide president for Codman Neuro Sciences. Kashuba also served as U.S. president for DePuy Spine. Kashuba received his B.S. in industrial engineering from Rutgers University.
Kashuba succeeds Paul Mraz, who earlier this year announced his intention to retire from the company. “The board would like to thank Paul for his years of service and leadership during which the company launched i-FACTOR™ bone graft in 25+ countries outside the U.S. and enrolled its U.S. IDE pivotal clinical trial,” Silverstein said.
Cerapedics also announced today that it named Jeffrey G. Marx, Ph.D., as its president and chief operating officer. Marx formerly served as vice president of corporate development at Orthovita, Inc. Marx had numerous other responsibilities as part of the senior leadership team during his 13-year tenure. Orthovita was a leading orthobiologics and biosurgery company that was acquired by Stryker for $318 million in 2011.
Following the acquisition, Marx led the integration of Orthovita into Stryker and served as vice president of corporate development at Stryker Orthobiologics. Marx received his B.S. in ceramic science and engineering from Penn State University and his Ph.D. in ceramic engineering from Missouri University of Science and Technology.
“I look forward to leading Cerapedics through the current FDA submission process and future product pipeline development. Rarely do you have the opportunity to introduce a whole new category within an established market like bone grafting, especially one with such potential to help doctors and patients achieve better outcomes with safety and reliability,” Marx said.
About Cerapedics, Inc.
Cerapedics, a 2012 Colorado Companies to Watch (COCTW) winner, is a medical device company focused on developing and commercializing novel osteobiologic products based upon its proprietary synthetic small peptide (P-15™) technology platform. i-FACTOR bone graft is the only biologic bone graft that utilizes a small peptide as an attachment factor intended to stimulate the natural bone healing process resulting in safe, predictable bone formation at a fraction of the cost of growth factors. i-FACTOR is currently available for sale in many countries outside the U.S.
CAUTION: i-FACTOR™ bone graft is not commercially available in the U.S. In the U.S., i-FACTOR bone graft is an investigational device limited by Federal Law (U.S.) to investigational use only.
More information can be found at www.cerapedics.com.
Steve McAdoo, +1-303-974-6275
Vice President of Marketing
Help employers find you! Check out all the jobs and post your resume.
comments powered by